# A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

> **NCT02203474** · PHASE2 · WITHDRAWN · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.**

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- COPD

## Interventions

- **DRUG:** Tiotropium HFA BAI 5 mcg
- **DRUG:** Tiotropium 18 mcg Capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02203474
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203474, "A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02203474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*